2026 Safety and Availability Communications
The FDA has established a listing page for Safety and Availability Communications issued throughout the year 2026 regarding biological products.
This affects manufacturers of biologics, blood products, and related therapeutic entities, as well as regulatory affairs and pharmacovigilance professionals responsible for monitoring agency safety signals.
The centralized listing serves as a primary repository for FDA's post-market safety signals and product shortage information. For regulatory teams, this suggests a need for routine surveillance of the page to ensure alignment with agency findings on product safety or availability, which may impact manufacturing schedules or reporting obligations.
Regulatory and pharmacovigilance teams should monitor this repository regularly for updates that may necessitate label changes, safety report submissions, or supply chain adjustments. Ensure internal communication channels are established to disseminate relevant safety notifications to clinical and manufacturing leads.